Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

President

Chief Executive Officer

CHIEF FINANCIAL OFFICER

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company.

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2023-05-05	Premium	bought	Premium	Premium	Premium	-
2022-11-23	Premium	bought	Premium	Premium	Premium	President
2021-12-20	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2021-08-17	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2021-06-11	Premium	bought	Premium	Premium	Premium	CHIEF FINANCIAL OFFICER
2021-06-09	Premium	bought	Premium	Premium	Premium	Chief Executive Officer

ELDN - Eledon Pharmaceuticals, Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for ELDN